Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma

Minerva Medica

Volumn 102, Issue 5, 2011, Pages 363-371

  Bertino, G ^a   Neri, S ^a   Bruno, C M ^a   Ardiri, A M ^a   Calvagno, G S ^a   Malaguarnera, M ^a,a   Toro, A ^a   Clementi, S ^a   Bertino, N ^a   Di Carlo, I ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alpha fetoproteins; Carcinoma, hepatocellular; Carcinoma, hepatocellular, diagnosis

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; IMMUNOGLOBULIN M; SQUAMOUS CELL CARCINOMA ANTIGEN;

CANCER DIAGNOSIS; COMPARATIVE STUDY; COMPLEX FORMATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PROGNOSIS; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTEMATIC REVIEW;

ALPHA-FETOPROTEINS; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOGLOBULIN M; LIVER NEOPLASMS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857603190     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43. (Pubitemid 33586866)
3. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-6. (Pubitemid 32911426)
4. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, Goedert JJ et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004;39:211-9. (Pubitemid 38461484)
5. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007;37(Suppl 2):S95-100.
6. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
7. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225-37. (Pubitemid 30123637)
8. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
9. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-19. (Pubitemid 34533556)
10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
11. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115-20. (Pubitemid 38240111)
12. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004;127:S17-26. (Pubitemid 39423366)
13. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127: S27-34. (Pubitemid 39423367)
14. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:S35-50. (Pubitemid 39423368)
15. Blum HE. Hepatocellular carcinoma: therapy and prevention. World Gastroeterol 2005;47:7391-400. (Pubitemid 43126017)
16. Di Bisceglie AM. Screening for hepatocellular carcinoma: being old is not all bad. Am J Gastroenterol 2004;99:1477-8. (Pubitemid 39180094)
17. Talwalkar JA, Gores GJ. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology 2004;127:S126-32. (Pubitemid 39423380)
18. Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma. Semin Liver Dis 2006;26:385-90. (Pubitemid 44632929)
19. Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark 2007;3:79-87.
20. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006;119:735-40. (Pubitemid 44051434)
21. Terentiev AA, Moldogazieva NT. Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc). 2006;71:120-32.
22. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2002;2:709-35. (Pubitemid 35469493)
23. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med 2007;45:1169-79. (Pubitemid 47396274)
24. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
25. Han SJ, Yoo S, Choi SH, Hwang EH. Actual half-life of alphafetoprotein as a prognostic tool in pediatric malignant tumours. Pediatr Surg Int 1997;12:599-602. (Pubitemid 27504061)
26. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993;18:990-7.
27. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37:1114-21. (Pubitemid 36538688)
28. Marrero JA, Lok AS. Newer markers for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S113-9. (Pubitemid 39423378)
29. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3.
30. Ueda N, Shiraha H, Fujikawa T, Takaoka N, Nakanishi Y, Suzuki M et al. Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy pro- thrombin production in hepatocellular carcinoma cell lines. Mol Oncol 2008;2:241-9.
31. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev 2007;31:35-44. (Pubitemid 46367447)
32. Bertino G, Ardiri AM, Boemi PM, Ierna D, Interlandi D, Caruso L et al. A study about mechanisms of desgamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med 2008;50:221-6.
33. Murata K, Sakamoto A. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: a possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2008;33:1149-55.
34. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of desgamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2009;35:1005-14.
35. Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect 2010;23:498-508.
36. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumour markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002;62:57-63. (Pubitemid 34702021)
37. Toyosaka A, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel. Am J Gastroenterol 1996;91:1610-5. (Pubitemid 26269180)
38. Mitsunobu M, Toyosaka A, Oriyama T, Okamoto E, Nakao N. Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel. Clin Exp Metastasis 1996;14:520-9. (Pubitemid 27006984)
39. Suzuki M, Shiraha H, Fujikawa T, et al. Des-gamma-carboxyl prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005;280:6409-15. (Pubitemid 40341187)
40. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum Markers of Hepatocellular Carcinoma. Dig Dis Sci 2010;55:2744-55.
41. Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009;16:2795-804.
42. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM et al. Des-gamma-Carboxy Prothrombin and alpha-Fetoprotein as Biomarkers for the Early Detection of Hepatocellular Carcinoma. Gastroenterology 2010;138:493-502.
43. Suminami Y, Kishi F, Sekiguchi K, Kato H. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem Biophys Res Commun 1991;181:51-8.
44. Kato H, Suehiro Y, Morioka H, Torigoe T, Myoga A, Sekiguchi K et al. Heterogeneous distribution of acidic TA-4 in cervical squamous cell carcinoma: immunohistochemical demonstration with monoclonal antibodies. Jpn J Cancer Res 1987;78:1246-50. (Pubitemid 18012968)
45. Giannelli G, Marinosci F, Sgarra C, Lupo L, Dentico P, Intonaci S. Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int J Cancer 2005;10:579-83. (Pubitemid 41099194)
46. mura Y, Pak SC, Luke C, Cataltepe S, Tsu C, Schick C et al. Circulating serpin tumour markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. Int J Cancer 2000;89:368-77.
47. Pontsso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG et al. Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 2004;90:833-7. (Pubitemid 38406594)
48. Guido M, Roskams T, Pontisso P, Fassan M, Thung SN, Giacomelli L et al. Squamous cell carcinoma antigen in human liver carcinogenesis. J Clin Pathol 2008;61:445-7. (Pubitemid 351518225)
49. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L et al. Squamous cell carcinoma antigen-immunoglobulin M complex as novel biomarkers for hepatocellular carcinoma. Cancer 2005;103:2558-65. (Pubitemid 40800535)
50. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E et at. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006;119:735-40. (Pubitemid 44051434)
51. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C et al. Monitoring SCCAIgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008;15:246-9. (Pubitemid 351326902)
52. Schneider SS, Schick C, Fish KE, Miller E, Pena JC, Treter SD et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci USA 1995;92:3147-51.
53. Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H, Whiteside TL. Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen. Br J Cancer 2000;82:981-9. (Pubitemid 30085255)
54. Suminami Y, Nagashima S, Murakami A, Nawata S, Gondo T, Hirakawa H et al. Suppression of a squamous cell carcinoma (SCO-related serpin, SCC antigen, inhibits tumour growth with increased intratumoural infiltration of killer cells. Cancer Res 2001;61:176-80.
55. Fujikawa T, Shiraha H, Yamamoto K. Significance of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Acta Med Okayama 2009;63:299-304.
56. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
57. Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995;75:2220-32.
58. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998;93:2452-6. (Pubitemid 29018554)
59. Franca AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004;37:1689-705. (Pubitemid 39555461)